Diabetic Neuropathy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Diabetic Neuropathy – Pipeline Review, H2 2017’, provides an overview of the Diabetic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy

The report reviews pipeline therapeutics for Diabetic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Neuropathy therapeutics and enlists all their major and minor projects

The report assesses Diabetic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics Inc

Angelini Group

Apollo Endosurgery Inc

Araim Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Bristol-Myers Squibb Co

Celgene Corp

Commence Bio Inc

Grifols SA

Grunenthal GmbH

Immune Pharmaceuticals Inc

Kineta Inc

KPI Therapeutics Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Neuralstem Inc

NovaLead Pharma Pvt Ltd

Novaremed Ltd

Omeros Corp

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

ViroMed Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Neuropathy - Overview 9

Diabetic Neuropathy - Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 17

Diabetic Neuropathy - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Diabetic Neuropathy - Companies Involved in Therapeutics Development 28

Achelios Therapeutics Inc 28

Angelini Group 28

Apollo Endosurgery Inc 28

Araim Pharmaceuticals Inc 29

Arena Pharmaceuticals Inc 29

Bristol-Myers Squibb Co 30

Celgene Corp 30

Commence Bio Inc 31

Grifols SA 31

Grunenthal GmbH 31

Immune Pharmaceuticals Inc 32

Kineta Inc 32

KPI Therapeutics Inc 32

Medifron DBT Co Ltd 33

Mitsubishi Tanabe Pharma Corp 33

Neuralstem Inc 34

NovaLead Pharma Pvt Ltd 34

Novaremed Ltd 34

Omeros Corp 35

Reata Pharmaceuticals Inc 35

Relief Therapeutics Holding AG 36

ViroMed Co Ltd 36

Diabetic Neuropathy - Drug Profiles 38

(amitriptyline + ketamine hydrochloride) - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

(diclofenac sodium + triclocarban) - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

A-100 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

AAD-2004 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

APD-371 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

atexakin alfa - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

BMS-002 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

BNV-222 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

cibinetide - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

CMB-200 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

CNV-2197944 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Cyndacel-M - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

immune globulin (human) - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

KCP-400 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

ketoprofen - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

KU-32 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Lpathomab - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

MDR-16523 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

MDR-652 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

MT-8554 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

NLP-198 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

NRD-135SE1 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

NSI-189 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

PDA-002 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

pirenzepine hydrochloride - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

RTA-901 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Small Molecules for CNS Disorders, Toxicology and Metabolic Disorders - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecules for Diabetic Neuropathy - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecules for Pain - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

sodium nitrite SR - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

trazodone hydrochloride - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

U-2902 - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

VM-202 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

XK-568b - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

Diabetic Neuropathy - Dormant Projects 102

Diabetic Neuropathy - Discontinued Products 105

Diabetic Neuropathy - Product Development Milestones 106

Featured News & Press Releases 106

Sep 25, 2017: ViroMed, Gene Therapy Powerhouse on Global Stage 106

Aug 02, 2017: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy 106

Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy 107

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 108

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 108

Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 110

Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial 110

Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 111

Feb 07, 2008: EpiCept Announces Encouraging Results Of Phase II Trial For NP-1 Cream In Diabetic Peripheral Neuropathy 111

Dec 03, 2007: Patient Enrollment Gets Completed In Phase IIb Trial Of EpiCept NP-1 In Diabetic Peripheral Neuropathy 112

Appendix 113

Methodology 113

Coverage 113

Secondary Research 113

Primary Research 113

Expert Panel Validation 113

Contact Us 113

Disclaimer 114

List of Tables

List of Tables

Number of Products under Development for Diabetic Neuropathy, H2 2017 10

Number of Products under Development by Companies, H2 2017 12

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Universities/Institutes, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Universities/Institutes, H2 2017 17

Number of Products by Stage and Target, H2 2017 19

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 20

Number of Products by Stage and Mechanism of Action, H2 2017 22

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 23

Number of Products by Stage and Route of Administration, H2 2017 25

Number of Products by Stage and Molecule Type, H2 2017 27

Diabetic Neuropathy – Pipeline by Achelios Therapeutics Inc, H2 2017 28

Diabetic Neuropathy – Pipeline by Angelini Group, H2 2017 28

Diabetic Neuropathy – Pipeline by Apollo Endosurgery Inc, H2 2017 29

Diabetic Neuropathy – Pipeline by Araim Pharmaceuticals Inc, H2 2017 29

Diabetic Neuropathy – Pipeline by Arena Pharmaceuticals Inc, H2 2017 29

Diabetic Neuropathy – Pipeline by Bristol-Myers Squibb Co, H2 2017 30

Diabetic Neuropathy – Pipeline by Celgene Corp, H2 2017 30

Diabetic Neuropathy – Pipeline by Commence Bio Inc, H2 2017 31

Diabetic Neuropathy – Pipeline by Grifols SA, H2 2017 31

Diabetic Neuropathy – Pipeline by Grunenthal GmbH, H2 2017 32

Diabetic Neuropathy – Pipeline by Immune Pharmaceuticals Inc, H2 2017 32

Diabetic Neuropathy – Pipeline by Kineta Inc, H2 2017 32

Diabetic Neuropathy – Pipeline by KPI Therapeutics Inc, H2 2017 33

Diabetic Neuropathy – Pipeline by Medifron DBT Co Ltd, H2 2017 33

Diabetic Neuropathy – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 34

Diabetic Neuropathy – Pipeline by Neuralstem Inc, H2 2017 34

Diabetic Neuropathy – Pipeline by NovaLead Pharma Pvt Ltd, H2 2017 34

Diabetic Neuropathy – Pipeline by Novaremed Ltd, H2 2017 35

Diabetic Neuropathy – Pipeline by Omeros Corp, H2 2017 35

Diabetic Neuropathy – Pipeline by Reata Pharmaceuticals Inc, H2 2017 36

Diabetic Neuropathy – Pipeline by Relief Therapeutics Holding AG, H2 2017 36

Diabetic Neuropathy – Pipeline by ViroMed Co Ltd, H2 2017 37

Diabetic Neuropathy – Dormant Projects, H2 2017 102

Diabetic Neuropathy – Dormant Projects, H2 2017 (Contd..1), H2 2017 103

Diabetic Neuropathy – Dormant Projects, H2 2017 (Contd..2), H2 2017 104

Diabetic Neuropathy – Discontinued Products, H2 2017 105

List of Figures

List of Figures

Number of Products under Development for Diabetic Neuropathy, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Number of Products by Top 10 Targets, H2 2017 18

Number of Products by Stage and Top 10 Targets, H2 2017 18

Number of Products by Top 10 Mechanism of Actions, H2 2017 21

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 21

Number of Products by Routes of Administration, H2 2017 24

Number of Products by Stage and Routes of Administration, H2 2017 24

Number of Products by Molecule Types, H2 2017 26

Number of Products by Stage and Molecule Types, H2 2017 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports